Preclinical mouse models have showed that combined administration of a fusion protein, consisting of a Fc domain and integrin targeting peptide, with albumin/IL-2 or anti-PD-1 immunotherapy was able to significantly enhance anti-tumor immunity and improve survival [119]. The gene discussed is IL2; the disease is neoplasm.